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Pittsburgh compound B imaging and
cerebrospinal fluid amyloid-b in a multicentre
European memory clinic study
Antoine Leuzy,1 Konstantinos Chiotis,1 Steen G. Hasselbalch,2 Juha O. Rinne,3,4
Alexandre de Mendonc¸a,5 Markus Otto,6 Alberto Lleo´,7,8 Miguel Castelo-Branco,9,10
Isabel Santana,11,12 Jarkko Johansson,4 Sarah Anderl-Straub,6 Christine A. F. von Arnim,6
Ambros Beer,13 Rafael Blesa,7,8 Juan Fortea,7,8 Sanna-Kaisa Herukka,14 Erik Portelius,15
Josef Pannee,15 Henrik Zetterberg,15,16 Kaj Blennow15 and Agneta Nordberg1,17
The aim of this study was to assess the agreement between data on cerebral amyloidosis, derived using Pittsburgh compound B
positron emission tomography and (i) multi-laboratory INNOTEST enzyme linked immunosorbent assay derived cerebrospinal
ﬂuid concentrations of amyloid-b42; (ii) centrally measured cerebrospinal ﬂuid amyloid-b42 using a Meso Scale Discovery enzyme
linked immunosorbent assay; and (iii) cerebrospinal ﬂuid amyloid-b42 centrally measured using an antibody-independent mass
spectrometry-based reference method. Moreover, we examined the hypothesis that discordance between amyloid biomarker
measurements may be due to interindividual differences in total amyloid-b production, by using the ratio of amyloid-b42 to
amyloid-b40. Our study population consisted of 243 subjects from seven centres belonging to the Biomarkers for Alzheimer’s and
Parkinson’s Disease Initiative, and included subjects with normal cognition and patients with mild cognitive impairment,
Alzheimer’s disease dementia, frontotemporal dementia, and vascular dementia. All had Pittsburgh compound B positron emis-
sion tomography data, cerebrospinal ﬂuid INNOTEST amyloid-b42 values, and cerebrospinal ﬂuid samples available for
reanalysis. Cerebrospinal ﬂuid samples were reanalysed (amyloid-b42 and amyloid-b40) using Meso Scale Discovery electroche-
miluminescence enzyme linked immunosorbent assay technology, and a novel, antibody-independent, mass spectrometry refer-
ence method. Pittsburgh compound B standardized uptake value ratio results were scaled using the Centiloid method.
Concordance between Meso Scale Discovery/mass spectrometry reference measurement procedure ﬁndings and Pittsburgh com-
pound B was high in subjects with mild cognitive impairment and Alzheimer’s disease, while more variable results were observed
for cognitively normal and non-Alzheimer’s disease groups. Agreement between Pittsburgh compound B classiﬁcation and Meso
Scale Discovery/mass spectrometry reference measurement procedure ﬁndings was further improved when using amyloid-b42/40.
Agreement between Pittsburgh compound B visual ratings and Centiloids was near complete. Despite improved agreement
between Pittsburgh compound B and centrally analysed cerebrospinal ﬂuid, a minority of subjects showed discordant ﬁndings.
While future studies are needed, our results suggest that amyloid biomarker results may not be interchangeable in some
individuals.
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Introduction
Current thinking ascribes the pathogenesis of Alzheimer’s
disease to the aggregation of amyloid-b in the brain.
Speciﬁcally, the accumulation of various species of aggre-
gated amyloid-b is believed to set in motion tau pathology
and neurodegeneration, leading to cognitive impairment
and, ultimately, dementia (Jack et al., 2013). Brain amyl-
oid-b accumulation can be identiﬁed in vivo using CSF
levels of the 42-amino acid form of amyloid-b (amyloid-
b42), and PET with ﬁbrillar amyloid-b speciﬁc radiotracers,
such as the carbon-11 labelled thioﬂavin-T derivative,
Pittsburgh compound B (PiB) (Blennow et al., 2015).
While brain retention of amyloid tracers such as PiB is
elevated in Alzheimer’s disease, CSF levels of amyloid-b42
are decreased, an observation hypothesized to reﬂect the
sequestration of brain soluble amyloid-b into insoluble pla-
ques, with a resultant reduction in the amount of amyloid-
b42 available for clearance into the CSF (Kawarabayashi
et al., 2001; DeMattos et al., 2002). This inverse relation-
ship has been conﬁrmed by many groups across cognitively
normal, mild cognitive impairment (MCI) and Alzheimer’s
disease subjects, leading to the view that these biomarkers
are interchangeable in deﬁning ‘amyloid-positivity’ (Fagan,
2015). Though this inverse relationship has generally been
observed between both measures, a subset of cases shows
discordant results, with either abnormal CSF amyloid-b42
but normal amyloid PET, or normal CSF amyloid-b42 but
abnormal amyloid PET (Forsberg et al., 2008; Jagust et al.,
2009; Degerman Gunnarsson et al., 2010; Landau et al.,
2013; Palmqvist et al., 2014; Zwan et al., 2014; Mattsson
et al., 2015). While discordance in most cases is due to
abnormal CSF amyloid-b42 in subjects with normal amyl-
oid PET, isolated PET positivity has been reported in both
MCI and Alzheimer’s disease (Koivunen et al., 2008;
Forsberg et al., 2010; Landau et al., 2013; Zwan et al.,
2014; Leuzy et al., 2015; Mattsson et al., 2015;
Palmqvist et al., 2016).
With the exception of a recent European multicentre
study (Zwan et al., 2016), however, large-scale studies ad-
dressing agreement between amyloid PET and CSF amyl-
oid-b42 have to date been conducted using cohorts
evaluated according to standardized clinical and biomarker
assessment protocols (Landau et al., 2013; Mattsson et al.,
2015; Palmqvist et al., 2016). In addition, there are no
studies comparing the agreement between amyloid PET
and CSF amyloid-b42 concentrations obtained by the
novel antibody-free mass spectrometry (MS)-based refer-
ence measurement procedure (RMP) (Leinenbach et al.,
2014). Moreover, there have as yet been no studies imple-
menting the Centiloid method, a recently proposed stand-
ardization approach that aims to facilitate cross-centre
comparison/combination of amyloid PET outcome data
using a scaling procedure (Klunk et al., 2015). The aim
of the present study was thus to assess agreement between
CSF amyloid-b42 and PiB PET in a mixed memory clinic
sample drawn from different academic European research
centres, with patients assessed according to local clinical
routines and imaged using differing acquisition protocols.
Given the established between-centre variability in enzyme-
linked immunosorbent assay (ELISA)-derived CSF amyloid-
b42 values (Wiltfang et al., 2007; Bjerke et al., 2010;
Andreasson et al., 2012; Mattsson et al., 2013), we like-
wise aimed to determine whether concordance rates would
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be affected by centralized reanalysis of CSF using
Meso Scale Discovery ELISA technology (MSD) and an
MS-based candidate RMP (Leinenbach et al., 2014).
Finally, we sought to examine the hypothesis that discord-
ance between amyloid biomarker results may be due to
interindividual differences in total amyloid-b production
(Wiltfang et al., 2007; Lewczuk et al., 2015), by adjusting
MSD and MS-RMP determined amyloid-b42 levels, for
those of amyloid-b40.
Materials and methods
Study population
Our study population consisted of 243 subjects for whom PiB
PET data and CSF data and samples were available, collected
across seven European academic centres belonging to the
Biomarkers for Alzheimer’s and Parkinson’s Disease
(BIOMARKAPD) initiative. Participating sites included the
Hospital de Sant Pau, Barcelona, Spain (n = 24); Coimbra
University Hospital, Coimbra, Portugal (n = 22); Danish
Dementia Research Centre, Copenhagen, Denmark (n = 31);
University of Lisbon, Lisbon, Portugal (n = 23); Karolinska
Institutet, Stockholm, Sweden (n = 32); Turku University
Hospital, Turku, Finland (n = 87); and the Ulm University
Hospital, Ulm, Germany (n = 24). Patients had been referred
for cognitive complaints and assessed according to standard
local clinical routines. All diagnoses were made in a multidis-
ciplinary team setting using a consensus-based approach.
Patients with Alzheimer’s disease (n = 122) fulﬁlled the 1984
National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) criteria
for probable Alzheimer’s disease dementia (McKhann et al.,
2011), with MCI (n = 81) diagnosed according to the
Petersen criteria (Petersen et al., 1999). Other diagnoses were
made according to the Neary criteria for frontotemporal de-
mentia (FTD; n = 20), including behavioural, semantic, and
progressive non-ﬂuent variants (Neary et al., 1998), and the
National Institute of Neurological Disorders and Stroke-
Association Internationale pour la Recherche et
l’Enseignement en Neurosciences (NINDS-AIREN) criteria for
vascular dementia (VaD; n = 7) (Roma´n et al., 1993).
In addition, 13 with normal cognition were recruited from
relatives and carers of patients. Inclusion criteria were: the
absence of memory or other cognitive complaints; independ-
ence in basic and instrumental activities of daily living; and no
active neurological or psychiatric disease. All subjects provided
written informed consent to participate in the investigation,
which was conducted according to the Declaration of
Helsinki and subsequent revisions. Ethical approval was ob-
tained from local regional ethics committees.
Apolipoprotein E genotype
Apolipoprotein E (APOE) genotyping was performed in a
subset of subjects (n = 106; four cognitively normal, 44 MCI,
52 Alzheimer’s disease, six FTD) via polymerase chain reaction
(PCR) of genomic DNA extracted from EDTA-anticoagulated
blood. Subjects were classiﬁed as e4 allele carriers or non-
carriers.
Local CSF amyloid-b42 and tau
measurements
All centres used a similar protocol for CSF collection and pro-
cessing. CSF samples were collected by lumbar puncture, be-
tween 8 am and 3pm. A total of 10ml was drawn, and stored
in polypropylene tubes. After removal of the ﬁrst 0.5ml, sam-
ples were centrifuged at 1500g (3000–4000 rpm) for 10min at
+ 4C. Samples were then stored at 80C in 1ml portions
pending biochemical analysis, without being thawed or re-
frozen. Amyloid-b42, total tau, and phosphorylated tau were
measured using commercially available sandwich ELISAs
(INNOTEST, Fujirebio-Europe), according to kit inserts.
Centralized CSF reanalysis for
amyloid-b
All CSF samples were those remaining from the clinical routine
at participating centres. Samples were stored on dry ice and
sent via express mail to the Clinical Neurochemistry
Laboratory, Gothenburg University, Mo¨lndal, Sweden. Given
the low volume of CSF available for reanalysis per centre
(500 ml), MSD was selected over the INNOTEST platform,
given its lower sample volume requirement. MSD electroche-
miluminescence analyses (amyloid-b42 and amyloid-b40) were
performed according to the manufacturer’s protocol. For cali-
bration and sample preparation for MS-RMP, native (un-
labelled) and 15N uniformly labelled amyloid-b40 and
amyloid-b42 and
13C uniformly labelled amyloid-b42
(rPeptide) were dissolved in 20% acetonitrile and 1% ammo-
nium hydroxide (NH4OH) to a concentration of 50 mg/ml.
Aliquots were stored at 80C. Artiﬁcial CSF was prepared
as described elsewhere (Dillen et al., 2011). Calibration sam-
ples for amyloid-b42 were prepared in human CSF as previ-
ously described (Leinenbach et al., 2014). For amyloid-b40,
artiﬁcial CSF was spiked to a ﬁnal concentration of 1.5, 5,
10, 20, 30 and 40 ng/ml native amyloid-b40 and a constant
concentration of 15N-amyloid-b40 at 1600 pg/ml as internal
standard. Unknown samples (180 ml) were spiked with 20 ml
internal standard to a ﬁnal concentration of 1600 pg/ml 13C-
amyloid-b42 and
15N-amyloid-b40. Solid phase extraction
(SPE), liquid chromatography, MS analysis and data process-
ing were conducted as previously described (Leinenbach et al.,
2014).
Determination of CSF amyloid-b
cut-offs
Local amyloid-b42 values (pooled) were classiﬁed as positive
(abnormal) or negative (normal) using an optimized cut-off of
557 pg/ml, established in a recent study using a large cohort of
BIOMARKAPD subjects (Zwan et al., 2016). Unbiased cut-
offs for MSD- and MS-RMP-derived amyloid-b42 and amyl-
oid-b42/40 ratios were determined by mixture modelling
(Benaglia et al., 2009), implemented in R (v.3.2.3, R
Foundation for Statistical Computing, Vienna, Austria, 2015).
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Pittsburgh compound B-PET imaging
PiB was synthesized using a previously described method at the
individual centres according to good manufacturing practice
requirements (Mathis et al., 2003; Klunk et al., 2004). PiB-
PET acquisition protocols varied across sites, with late sum-
mation images created according to local clinical practice:
Barcelona, four 5-min frames, 50- to 70-min post-injection
(50- to 70-min summation); Coimbra, Lisbon, Stockholm,
60-min dynamic acquisition (40- to 60-min summation);
Copenhagen, 30-min dynamic acquisition, 40-min post-
injection (40- to 70-min summation); Turku, 30-min dynamic
acquisition 60min post-injection (60- to 90-min summation),
and Ulm, four 5-min frames, 40- to 60-min post-injection (40-
to 60-min summation). PiB summation images were rated lo-
cally by nuclear medicine physicians as either positive (binding
in more than one cortical region; abnormal) or negative (pre-
dominantly white matter binding; normal), blinded to CSF
results.
Pittsburgh compound B-PET image
analysis
PiB summation images (40–60, 40–70, 50–70, and 60–90min)
were ﬁrst non-linearly spatially normalized to a population-
based PiB template (Nordberg et al., 2013), using the normal-
ize function in SPM8 (Functional Imaging Laboratory,
Wellcome Department of Imaging Neuroscience, UCL,
London, UK). Spatially normalized images were then
resampled using a 23-region grey matter atlas, created in par-
allel to the PiB template (Nordberg et al., 2013). Standardized
uptake value ratio (SUVr) images were then calculated by nor-
malizing PiB uptake within frontal, temporal, parietal, occipi-
tal, parahippocampal, anterior and posterior cingulate regions
to mean cerebellar grey matter uptake.
Owing to between-centre variability in PiB scanning win-
dows, SUVr data were standardized using a recent method
that allows for linear scaling of amyloid PET outcome data
to a 100-point scale (Klunk et al., 2015), the units of which
have been termed ‘Centiloids’. After downloading de-identiﬁed
PiB and MRI data from the Global Alzheimer’s Association
Information Network website (GAAIN; http://www.gaain.
org) for 34 amyloid-negative young controls (YC-0) and 45
amyloid-positive Alzheimer’s disease subjects (AD-100), we
conﬁrmed the validity of our analysis pipeline via replication
of the Level 1 analysis (linear correlation between down-
loaded/recalculated PiB Centiloid values: slope of 0.99, inter-
cept of 1.03, and R2 of 0.99; Fig. 1) (Klunk et al., 2015). As a
result of having scanning intervals up to 90min, we were re-
stricted to the subset of subjects with PET data over this time
interval (0–90min; 16 YC-0 and 40 AD-100) in the Level 2
calibration of our non-standard approach. Following exclusion
of scans where there had been difﬁculty with subject position-
ing in the scan ﬁeld, the ﬁnal sample used to derive slope and
intercept parameters for calculation of ‘PiB calculated’ SUVr
values (PiB-CalcSUVr), were 11 for YC-0 and 35 for AD-100.
After comparing SUVr values obtained using both standard
(50–70min, global cortical target region and whole cerebellum
reference volumes of interest) and non-standard approaches
via linear regression (PiBUNITIND: R
2 between 0.96 and
0.97), PiB-CalcSUVr data for each of the four time windows
was converted into Centiloid values (PiBCentiloidstd YC-0: SD
between 6.62 and 25.4, relative variance between 0.26 and
5.17; PiBCentiloidstd AD-100: SD between 21.31 and 22.95,
relative variance between 1 and 1.08), using the mean SUVr
of the 34 YC-0 and 45 AD-100 subjects.
To set a threshold for PiB positivity using Centiloids, we
adopted a composite cortical SUVr cut-off of 1.41, represent-
ing the upper 95% conﬁdence limit from a previously charac-
terized population of normally distributed healthy controls for
whom PiB data have been acquired 40–60min after injection
(Nordberg et al., 2013). Using 40–60-min slope and intercept
parameters, this cut-off was converted to Centiloid units,
giving a cut-off of 34. This value was then used to subdivide
subjects into PiB + (434) and PiB (434).
Statistical analysis
Statistical analyses were performed with R, v.3.2.3. Between-
group comparisons were done using Kruskal-Wallis ANOVA
for continuous values and chi-square (sex, education) or
Fisher’s exact tests (APOE) for categorical values. Post hoc
Mann Whitney U-tests were performed where appropriate.
These analyses were corrected for multiple comparisons using
false discovery rate (FDR). The ratio of amyloid-b42 to amyl-
oid-b40 (MSD and MS-RMP) was calculated according to a
previously published formula: [(amyloid-b42) / (amyloid-
b40)  10] (Hansson et al., 2007). Linear regression analyses
were performed to assess the relationship between values from
the different CSF analytical platforms, as well as between pub-
lished Centiloid values and those calculated at our site.
Concordance between PiB PET (visual, Centiloid) and CSF
(amyloid-b42, amyloid-b42/40) was deﬁned as the proportion of
subjects positive or negative for both biomarkers (i.e. concord-
ant positive, PiB + /CSF + , or concordant negative, PiB/
CSF). Discordance between PiB and CSF was deﬁned as
the proportion of individuals with only one abnormal bio-
marker (i.e. discordant with PiB positivity, PiB + /CSF, or
Figure 1 Linear correlation plot showing the relationship
between original/recalculated PiB Centiloids. Original
(Pittsburgh) and recalculated (Stockholm) PiB Centiloids are shown
on the ordinate and abscissa, respectively (YC-0, n = 34; AD-100,
n = 45).
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discordant with CSF positivity, PiB/CSF + ). Agreement be-
tween visual and Centiloid based classiﬁcation was assessed
using percentage agreement and Fleiss k.
Results
Participant characteristics and CSF
mixture modelling cut-offs
Subject characteristics according to diagnostic group are
presented in Table 1. Groups did not differ in terms of
age, sex, education, or in the period between CSF and
PiB PET assessments. As expected, MMSE scores were
lower in patient groups, relative to cognitively normal sub-
jects (MCI, Alzheimer’s disease, FTD, P5 0.001; VaD,
P = 0.01), and differed between patient groups
(MCI4Alzheimer’s disease and FTD, P5 0.001). No sig-
niﬁcant differences in the prevalence of the APOE e4 allele
were found between groups. Levels of total tau were higher
in Alzheimer’s disease with respect to cognitively normal
subjects (P5 0.001), FTD and VaD (P50.01). Compared
to cognitively normal subjects, phosphorylated tau levels
were higher in MCI and Alzheimer’s disease (P5 0.01
and 0.001, respectively) and, relative to MCI, higher in
Alzheimer’s disease (P50.001). Phosphorylated tau was
also found to be higher in Alzheimer’s disease, compared
to FTD and VaD (P5 0.001). The unbiased cut points to
identify an abnormal concentration of amyloid-b in CSF
were 5515 pg/ml and 0.72 (MSD amyloid-b42 and amyl-
oid-b42/40, respectively) and 5896 pg/ml and 0.76 (MS-
RMP amyloid-b42 and amyloid-b42/40, respectively).
Pittsburgh compound B PET findings
The proportion of PiB scans visually rated as positive was
greatest in Alzheimer’s disease (93%), followed by MCI
(62%), FTD (15%), cognitively normal (8%), and VaD
(0%). Global Centiloid was higher in patient groups in
comparison to cognitively normal (MCI, Alzheimer’s dis-
ease, P5 0.001), in Alzheimer’s disease, FTD, and VaD,
in comparison to MCI (P5 0.001, 0.001, 0.01, respect-
ively) and in Alzheimer’s disease, relative to FTD and
VaD (P5 0.001). No difference was found between FTD
and VaD.
CSF amyloid-b findings
Locally measured INNOTEST and reanalysed CSF levels
(Table 2) were lower in patients, relative to controls
(P5 0.05), with levels in Alzheimer’s disease lower than
those in MCI (P5 0.001). Using MSD and MS-RMP,
amyloid-b42 concentrations were lower in MCI (P5 0.05)
and Alzheimer’s disease (P5 0.001), with respect to cogni-
tively normal subjects. Further, amyloid-b42 values were
lower in Alzheimer’s disease CSF, compared to MCI
(P5 0.001), FTD, and VaD (P5 0.01). Findings using
the ratio of amyloid-b42 to amyloid-b40 were in agreement
with those for amyloid-b42: cognitively normal versus MCI
(P5 0.001), MCI versus Alzheimer’s disease (P5 0.001),
Alzheimer’s disease versus FTD (P5 0.001) and VaD
(P5 0.01). No between-group differences were found for
amyloid-b40.
Relative to INNOTEST, amyloid-b42 concentrations were
lower using MSD, and higher using MS-RMP; this pattern
Table 1 Demographic, clinical and biomarker characteristics according to diagnostic group
CN MCI AD FTD VaD
(n = 13) (n = 81) (n = 122) (n = 20) (n = 7)
Age, years 67 (69, 60) 64 (70, 58) 65 (72, 59) 64 (70, 60) 61 (74, 57)
Sex, M: F (% F) 6: 7 (54%) 37: 44 (54%) 50: 72 (59%) 9: 11 (55%) 3: 4 (57%)
Education, 1–4 3 (4, 2.8) 3 (4, 2) 3 (3, 2) 2 (3, 2) 2 (3, 1.5)
MMSE, points 29 (30, 28) 27 (28, 26) 23 (26, 20) 23 (27, 20) 26 (27.5, 22.5)
APOE "4, 5 1 allele† 4 (0%) 25 (57%) 29 (56%) 2 (33%) N/A
INNOTEST Ab42, pg/ml 843 (900, 732) 535 (698, 409) 413 (530, 308) 641 (726, 433) 491 (675.5, 386.5)
INNOTEST Ab42 positive 1 (8%) 46 (57%) 96 (79%) 10 (50%) 5 (71%)
INNOTEST T-tau, pg/mla 252 (318, 204) 313 (520, 210) 488 (772, 326) 307 (409, 193) 261 (306, 219)
INNOTEST P-tau, pg/mlb 43 (58, 33) 59 (77, 43) 74 (107, 57) 43 (64, 31) 41 (48, 28)
CSF-PiB, months 2.63 (7.05, 1.55) 3.93 (8.30, 1.77) 2.43 (5.14, 0.74) 2.03 (3.87, 1.09) 3.47 (5.20, 2.93)
PiB positive (Visual) 1 (8%) 50 (62%) 114 (93%) 3 (15%) 0 (0%)
PiB, SUVr 1.26 (1.32, 1.21) 1.54 (1.87, 1.24) 1.83 (2.05, 1.67) 1.18 (1.25, 1.09) 1.25 (1.27, 1.11)
PiB, Centiloid 15.1 (20.8, 8.3) 47.5 (87.6, 10.9) 84.1 (110.8, 63.1) 4.6 (13.8, 5.9) 12.8 (14.7, -3.9)
PiB positive (Centiloid) 1 (8%) 47 (58%) 112 (92%) 3 (15%) 0 (0%)
Values are reported as median (quartile3, quartile 1), or as n (%). PiB SUVr and Centiloid refer to global cortical composite.
Ab42 = amyloid-b42; AD = Alzheimer’s disease; APOE "4 = "4 allele of apolipoprotein E; CN = cognitively normal older individuals; MMSE = Mini-Mental State Examination;
N/A = not applicable; P-tau = tau hyperphosphorylated at threonine 181: T-tau = total tau.
Owing to between country differences, a 4-point scale was used for educational level: 1 = basic schooling, 2 = professional training, 3 = college education, 4 = university degree.
aData missing for nine cognitively normal, 37 MCI, 70 Alzheimer’s disease, 14 FTD, and seven VaD subjects.
bData missing for three MCI, three Alzheimer’s disease, one FTD, and one VaD subject.
cData missing for eight MCI, 16 Alzheimer’s disease, and three FTD subjects.
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held across all groups, save for VaD subjects, where the
inverse was found. For all subjects, however, MS-RMP
amyloid-b40 levels were higher than those for MSD. Only
minor differences were seen between platforms when using
the ratio of amyloid-b42 to amyloid-b40. The correlation
between local and centralized CSF measurements was mod-
erate (INNOTEST amyloid-b42 and amyloid-b42 from MSD
and MS-RMP: Spearman’s r = 0.74, P5 0.001; Spearman’s
r = 0.74, P5 0.001, Fig. 2A and B, respectively), but
high between the new, centralized measurements (MSD
and MS-RMP): (amyloid-b42, Spearman’s r = 0.93,
P50.001, Fig. 2C; amyloid-b42/40, Spearman’s r = 0.91,
P50.001, Fig. 2D).
Agreement between visual and
Centiloid-based Pittsburgh com-
pound B classification
Across groups, agreement between visual and Centiloid
based PiB ratings was 97% (235 of 243; Cohen
k = 0.92). Of the eight instances of disagreement, six
(75%) were rated as visually positive, Centiloid negative
(four MCI, two Alzheimer’s disease), and two as visually
negative, Centiloid positive (one cognitively normal, one
MCI). While discordance rates in FTD and VaD between
visual assessment and Centiloid did not differ, rates in MCI
were consistently higher when using Centiloid, with mixed
ﬁndings in cognitively normal and Alzheimer’s disease sub-
jects (Table 3).
Concordance between PiB Centiloid
and CSF amyloid-b
Using the total sample set, the concordance between PiB and
CSF amyloid-b42 concentrations measured by INNOTEST,
MSD and MS-RMP were 73%, 77% and 76%, respectively
(Figs 3, 4A and B). Using the ratio of amyloid-b42 to amyl-
oid-b40 further improved the concordance (MSD, 90%; MS-
RMP 88%, see Fig. 4C and D).
Using reanalysed amyloid-b42, concordance was highest
in Alzheimer’s disease and MCI, with ﬁndings for cogni-
tively normal, FTD, and VaD varying between MSD and
MS-RMP techniques. In VaD subjects, discordance was the
same as INNOTEST using MS-RMP, but lower using
MSD; while across FTD, MCI, and cognitively normal sub-
jects, discordance was higher using MSD and MS-RMP.
Across all groups, however, the ratio of amyloid-b42 to
amyloid-b40 was better than when using amyloid-b42
alone, with the greatest change seen in the VaD group.
When looking at discordance with local amyloid-b42, PET
was overall more often abnormal than CSF, with isolated
CSF positivity predominant when using the reanalysed data
(Fig. 5).
Comparison of concordant and
discordant subjects
Comparison of subjects showing concordant and discord-
ant amyloid biomarker results are shown in Supplementary
Tables 1–5. Using INNOTEST amyloid-b42, total and
phosphorylated tau were found to be higher in concordant
positive subjects, relative to those concordant negative and
those discordant with abnormal CSF. Tau levels were like-
wise found to higher the discordant PET positive group,
relative to both discordant with isolated abnormal CSF
and discordant negative subgroups (Supplementary Table
1). When using reanalysed CSF values, the prevalence of
the APOE e4 allele was found to be higher in those con-
cordant positive, relative to those concordant negative. Age
differences were noted between groups deﬁned using MSD
and MS-RMP amyloid-b42, though ﬁndings were not
Table 2 Results for INNOTEST and reanalysed CSF according to diagnostic group
CN MCI AD FTD VaD
(n = 13) (n = 81) (n = 122) (n = 20) (n = 7)
INNOTEST Ab42, pg/ml 843 (900, 732) 535 (698, 409) 413 (530, 309) 641 (726, 433) 491 (675.5, 386.5)
Ab42 positive 1 (8%) 46 (57%) 96 (79%) 10 (50%) 5 (71%)
MSD Ab40, pg/ml 5363 (7369, 4425) 5607 (7188, 4536) 5476 (6556, 4333) 5213 (6149, 4225) 5187 (6180, 4499)
Ab42, pg/ml 524 (719, 428) 352 (510, 249) 258 (374, 193) 448 (556, 300) 529 (630, 369)
Ab42, positive 6 (46%) 60 (74%) 115 (94%) 12 (60%) 3 (43%)
Ab42/Ab40 0.97 (1.17, 0.85) 0.60 (0.89, 0.48) 0.51 (0.57, 0.42) 0.93 (1.05, 0.78) 1.03 (1.05, 0.79)
Ab42/Ab40 positive 3 (23%) 52 (64%) 113 (93%) 7 (35%) 2 (29%)
MS-RMP Ab40, pg/ml 9305 (12647, 7301) 8619 (11493, 6324) 8160 (10903, 6353) 7788 (9715, 6590) 7510 (9982, 5762)
Ab42, pg/ml 956 (1286, 654) 568 (863, 396) 441 (617, 318) 704 (968, 484) 760 (1060, 498)
Ab42 positive 6 (46%) 63 (78%) 115 (94%) 14 (70%) 5 (71%)
Ab42/Ab40 0.96 (1.01, 0.76) 0.61 (0.92,0.47) 0.5 (0.6, 0.38) 0.91 (1.06, 0.38) 1.02 (1.10, 0.81)
Ab42/Ab40 positive 3 (23%) 58 (72%) 117 (96%) 10 (50%) 2 (29%)
Values are reported as median (quartile3, quartile 1), or as n (%).
Ab = amyloid-b; AD = Alzheimer’s disease; CN = cognitively normal older individuals; MMSE = Mini-Mental State Examination.
Cut-offs used to determine positivity were as follows: INNOTEST amyloid-b42, 5557 pg/ml; MSD amyloid-b42, 5515 pg/ml; MSD amyloid-b42/40, 50.72; MS amyloid-b42, 5896 pg/
ml; MS amyloid-b42/40, 5 0.76.
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consistent. Similarly, a greater percentage of females was
found in the concordant positive group for MSD amyloid-
b42/40, relative to PiB/CSF, though for MS-RMP amyl-
oid-b42, a greater percentage of females was noted in the
PiB/CSF + group, relative to those concordant positive.
Mini-Mental State Examination scores were lower in
those with concordant positive ﬁndings, relative to those
concordant negative; ﬁndings, however, varied across plat-
forms in comparison to the other biomarker pairings. With
respect to the interval between CSF and PET, only for MS-
RMP amyloid-b42 was a difference found (PiB + /CSF 4
PiB + /CSF + and PiB/CSF + , P5 0.05). Supplementary
Fig. 1 shows the relationship between concordance
(INNOTEST amyloid-b42 and PiB Centiloids) and CSF
tau ﬁndings.
Discussion
Here, we report concordance levels between PiB PET and
CSF amyloid-b (amyloid-b42 and amyloid-b42/40) using
subjects from the European BIOMARKAPD initiative.
Despite good agreement between these measures, discord-
ance was observed in a subset of patients across all groups,
using both local and centrally analysed measurements.
Given the well-described intra- and intercentre variability
in CSF amyloid-b42 concentrations using INNOTEST
ELISA (Mattsson et al., 2011), it was expected that con-
cordance with PiB would be increased using reanalysed
measurements. Comparison of discordance using local
and reanalysed CSF, however, yielded variable results,
with improved agreement with PiB classiﬁcation seen only
in the Alzheimer’s disease patients using reanalysed amyl-
oid-b42—and VaD, when using MSD amyloid-b42—and
across patient groups when using amyloid-b42/40. This pat-
tern may suggest that the reanalysed results are a more
faithful approximation of amyloid-b42 levels across
groups, the centralized analysis component having removed
the variance imposed by differences in INNOTEST meas-
urements between laboratories. While it is thus tempting
to speculate that MSD and MS-RMP providing more ac-
curate estimates of amyloid-b42 concentration levels, this
Figure 2 Linear correlation plots showing the relationship between locally and centrally measured CSF amyloid-b. (A)
INNOTEST and MSD amyloid-b42; (B) INNOTEST and MS-RMP amyloid-b42; (C) MSD and MS-RMP amyloid-b42; and (D) MSD and MS-RMP
amyloid-b42/40.
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explanation seems unlikely since these analytical techniques
have been shown to correlate tightly—both with one an-
other, and with INNOTEST—when samples are analysed
in a single run under standardized conditions (Bjerke et al.,
2016).
As expected, concordance rates matched closely across
groups using MSD and MS-RMP. Relative to MSD, MS-
RMP classiﬁed an additional four patients (one in both the
MCI and FTD groups, two in VaD group) as CSF positive
using amyloid-b42, and one cognitively normal subject
using amyloid-b42/40. Concordance ﬁndings using the
ratio of amyloid-b42 to amyloid-b40—a measure which
adjusts for ‘high’ and ‘low’ amyloid-b production levels,
and thus for false negative (just above the cut-off) and
false positive amyloid-b42 results, respectively (Wiltfang
et al., 2007; Lewczuk et al., 2015)—were, as expected,
greater than when using amyloid-b42 alone. This effect
was greatest in the FTD and VaD groups. Though based
on a relatively small sample size, this ﬁnding ties into recent
work showing that subcortical changes non-speciﬁc to
Alzheimer’s disease may alter global levels of amyloid-b
isoforms (Janelidze et al., 2016; van Westen et al., 2016).
This raises the possibility that the amyloid-b42/40 ratio may
allow for differentiating conditions in which amyloid-b40
and amyloid-b42 can be reduced in parallel, from true amy-
loid-positive cases. Future studies, however, will be needed
to better understand the relationship between Alzheimer’s
disease pathology and vascular changes, as well as matrix
effects on amyloid-b42 measurements.
PiB-PET scans in the present study ranged from 40- to
90-min post-injection, with 20- or 30-min time windows
used to normalize global cortical uptake to that within
Table 3 Discordance findings between PiB and CSF across the various platforms investigated and using both visual
and Centiloid
CN MCI AD FTD VaD
(n = 13) (n = 81) (n = 122) (n = 20) (n = 7)
Visual Centiloid Visual Centiloid Visual Centiloid Visual Centiloid Visual Centiloid
INNOTEST Ab42, PiB 2 (15%) 3 (23%) 18 (22%) 20 (25%) 29 (24%) 30 (25%) 9 (45%) 9 (45%) 5 (71%) 5 (71%)
PiB + /CSF 1 2 11 10 23 23 2 2 0 0
PiB/CSF + 1 1 7 10 6 7 7 7 5 5
MSD Ab42, PiB 7 (54%) 6 (46%) 18 (22%) 21 (26%) 12 (10%) 13 (11%) 9 (45%) 9 (45%) 3 (43%) 3 (43%)
PiB + /CSF 1 1 4 4 5 5 0 0 0 0
PiB/CSF + 6 5 14 17 7 8 9 9 3 3
Ab42/Ab40, PiB 2 (15%) 3 (23%) 6 (7%) 12 (15%) 6 (5%) 6 (5%) 4 (20%) 4 (20%) 2 (29%) 2 (29%)
PiB + /CSF 0 1 2 3 3 3 0 0 0 0
PiB/CSF + 2 2 4 9 3 3 4 4 2 2
MS-RMP Ab42, PiB 7 (54%) 6 (46%) 21 (26%) 25 (31%) 12 (10%) 13 (11%) 11 (55%) 11 (55%) 5 (71%) 5 (71%)
PiB + /CSF 1 1 4 4 5 5 0 0 0 0
PiB/CSF + 6 5 17 21 7 8 11 11 5 5
Ab42/Ab40, PiB 3 (23%) 4 (31%) 10 (12%) 14 (17%) 8 (7%) 9 (7%) 7 (35%) 7 (35%) 2 (29%) 2 (29%)
PiB + /CSF 0 1 1 1 2 2 0 0 0 0
PiB/CSF + 3 3 9 13 6 7 7 7 2 2
Values are reported as n or n (%).
AD = Alzheimer’s dementia; Ab42 = amyloid-b42; Ab42/40 = amyloid-b42/40; CN = cognitively normal older individuals; MMSE = Mini-Mental State Examination.
Figure 3 Scatterplot showing concordance between
INNOTEST amyloid-b42 and PiB Centiloids. Circles indicate
cognitively normal subjects, triangles MCI, squares Alzheimer’s dis-
ease, crosses FTD, and crossed squares VaD. The vertical line re-
flects the Centiloid cut-off of 34; the horizontal line the cut-off of
557 pg/ml for INNOTESTamyloid-b42. Blue indicates PiB scans were
visually rated as negative, red as positive. The grey quadrants indi-
cate concordance between amyloid-b biomarkers (top left, con-
cordant negative: PiB/CSF; bottom right, concordant positive:
PiB + /CSF +). The white quadrants indicate discordance between
amyloid-b biomarkers (bottom left, discordant with isolated CSF
positivity: PiB/CSF + ; top right, discordant with isolated PiB posi-
tivity: a PiB + /CSF).
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the cerebellar grey matter. Given that the range of PiB
SUVr values using this reference tissue have been shown
to vary dynamically over time (Lopresti et al., 2005;
McNamee et al., 2009), the Centiloid approach was imple-
mented to ensure appropriate comparability of imaging re-
sults. In line with previous studies using visual and
quantitative-based reads (Rabinovici et al., 2011; Mountz
et al., 2015), high agreement was observed between both
classiﬁcation methods, with all cases rated as visually posi-
tive, Centiloid negative, exhibiting values close to the cut-
off. Though few in number, these cases highlight that sub-
jects with borderline positive values can prove visually chal-
lenging and contribute to discrepant interpretations across
assessment approaches. In the two subjects classiﬁed as
amyloid-positive using Centiloids and negative using
visual assessment, the pattern of cortical uptake was
unclear owing to atrophy, high white matter signal, and
poor image quality. Though the clinical use of amyloid-
PET in routine clinical practice will likely depend on
visual assessment alone, our ﬁndings suggest that
Centiloid ratings can be used independently, or as a valu-
able adjunct to visual reads in multicentre studies.
The global composite PiB SUVr cut-off of 1.41 was se-
lected for use in the present study owing to it having been
previously established using our processing pipeline, and
due to the fact that we were restricted to the use of a
PiB-PET template owing to limited availability of structural
imaging in our study population. Though somewhat more
conservative than the only other Centiloid cut-off of 27.78
available in the literature (Ayakta et al., 2016), our
higher cut-off reﬂects differences in populations, method
for cut-off selection, and processing pipelines, including
Figure 4 Scatterplots reflecting concordance between PiB Centiloids and reanalysed CSF. (A) MSD amyloid-b42 (cut-off5 515 pg/
ml). (B) MSD amyloid-b42/40 (cut-off5 0.72); (C) MS-RMP amyloid-b42 (cut-off5 896 pg/ml), and (D) MS-RMP amyloid-b42/amyloid-b40 (cut-
off5 0.76). Grey circles indicate cognitively normal healthy control subjects, triangles indicate MCI, squares indicate Alzheimer’s disease, crosses
FTD, and crossed squares VaD. The vertical lines reflects the Centiloid cut-off of 34; the horizontal lines the cut-offs of5 515 pg/ml,50.72,
5896 pg/ml, and 50.76 for MSD (amyloid-b42, amyloid-b42/40) and MS-RMP (amyloid-b42, amyloid-b42/40), respectively. Blue indicates PiB scans
visually rated as negative, red as positive. The grey quadrants indicate concordance between amyloid-b biomarkers (top left, concordant negative:
PiB/CSF; bottom right, concordant positive: PiB + /CSF +). The white quadrants indicate discordance between amyloid-b biomarkers (bottom
left, discordant with isolated CSF positivity: PiB/CSF + ; top right, discordant with isolated PiB positivity: a PiB + /CSF). Ab = amyloid-b.
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the choice of scanning window and volumes of interest. For
instance, our approach used slope and intercept parameters
from a 40–60min post-injection interval to determine
Centiloid equivalence to our SUVr cut-off (in contrast to
50–70 min), itself established using the 95th percentile ap-
proach in healthy older subjects [versus receiver operating
characteristic (ROC) curve in a mixed patient population,
with CERAD score as standard of truth]. Indeed, back cal-
culation of the 27.78 Centiloid cut-off to SUVr using our
pipeline yielded an SUVr close to ours (1.38), highlighting
the effects of varying analysis methods, the resulting limited
comparability of SUVr data across centres, and the attend-
ant importance of Centiloid standardization.
Classiﬁcation mismatch using PiB and amyloid-b42 may
be due a number of factors. Most mismatched subjects in
our study had isolated low CSF amyloid-b. In some indi-
viduals, this was due PiB retention being only somewhat
elevated, and thus falling below the cut point for positivity.
In addition, since PiB binds only weakly to amorphous
amyloid-b plaques (Bacskai et al., 2007; Ikonomovic
et al., 2008), PiB prove unable to detect variants of
Alzheimer’s disease characterized by the predominance of
diffuse (non-ﬁbrillar) plaques (Cairns et al., 2009; Scho¨ll
et al., 2012). Of course low amyloid-b42 in CSF is also
known to occur in isolation in non-Alzheimer’s disease con-
ditions (Ewers et al., 2015; Skillba¨ck et al., 2015) and may
also be related to entrapment in interstitial drainage path-
ways (Weller et al., 2001), epitope masking due to binding
of amyloid-b42 to carrier proteins (Otto et al., 2000;
Wiltfang et al., 2003), or the presence of amyloid as a
secondary pathology. In cognitively normal subjects, abnor-
mal CSF amyloid-b42 can also be seen, and is thought to
possibly represent preclinical Alzheimer’s disease (Fagan
et al., 2009a; Sperling et al., 2011; Palmqvist et al.,
2016). Isolated increased PiB uptake using INNOTEST
data likely reﬂected between-centre variability in
INNOTEST results; using reanalysed data, however, this
pattern was infrequent and was seen mainly in MCI and
Alzheimer’s disease. This ﬁnding may in some cases be due
to cut-off levels but may also reﬂect the possibility that
ﬁbrillar amyloid-b can be detected ﬁrst in some individuals,
as has been reported previously (Koivunen et al., 2008;
Forsberg et al., 2010; Landau et al., 2013).
Among the studies that have thus far examined the asso-
ciation between amyloid PET and CSF amyloid-b42 (Fagan
et al., 2006, 2007, 2009b; Forsberg et al., 2008, 2010;
Jagust et al., 2009; Tolboom et al., 2009; Degerman
Gunnarsson et al., 2010; Weigand et al., 2011; Landau
et al., 2013; Zwan et al., 2014, 2016; Palmqvist et al.,
2014, 2016; Mattsson et al., 2015), few have directly com-
pared tau levels in those with concordant and discordant
biomarker results. In the studies that have, tau was found
to be higher in PET+ /CSF+ subjects, relative to those
PET/CSF + (Palmqvist et al., 2016; Zwan et al., 2016),
in PET+ /CSF + subjects, relative to those PET/CSF +
(Mattsson et al., 2015; Zwan et al., 2016), and in subjects
discordant with PET positivity, relative to both those con-
cordant negative and discordant with abnormal CSF (Zwan
et al., 2016). Using INNOTEST amyloid-b42, our ﬁndings
match those reported up to now. Comparison of tau levels
between biomarker subgroups deﬁned using reanalysed
CSF, however, was not performed, due to differences in
CSF methodology (INNOTEST versus xMAP Luminex
multiplexing). Though group differences were noted for
gender and APOE in the present study, in the aggregate
with ﬁndings from other studies (Mattsson et al., 2015;
Toledo et al., 2015), the precise modulatory role exerted
by these variables is not yet clear. Lastly, concordance ﬁnd-
ings here reported are unlikely to have been much altered
by inclusion of CSF tau data, with the majority of abnor-
mal tau values clustered in the concordant positive quad-
rant. Future studies incorporating new approaches for CSF
tau quantiﬁcation and multivariate modelling are required
to further clarify differences between biomarker subgroups.
Though discordance between CSF and amyloid-b PET
has thus far been discussed primarily in the context of
the increasing use of these two techniques in the diagnosis
Figure 5 Frequency plots showing different agreement
profiles between PiB PET and CSF. Values of 5557 pg/ml
(INNOTEST amyloid-b42), 5515 pg/ml (MSD amyloid-b42), 50.72
(MSD amyloid-b42/40), 5896 pg/ml (MS-RMP amyloid-b42), 50.76
(MS-RMP amyloid-b42/40), and global Centiloid value4 34 were
used to classify subjects as concordant positive (PiB + /CSF +),
concordant negative (PiB/CSF), discordant with CSF positivity
(PiB/CSF + ), and discordant with PiB positivity (PiB + /CSF).
Ab = amyloid-b.
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of cognitively impaired individuals, an additional area of
importance is that of future clinical trials. In one of the
largest studies conducted so far on the relationship between
amyloid-b biomarkers, it was shown that concordance
increased signiﬁcantly as a function of disease stage
(Mattsson et al., 2015), with the highest levels of discord-
ance noted in cognitively normal and subjective memory
complaint subjects. In a related study focusing on non-de-
mented subjects diagnosed as cognitively healthy controls
or MCI, evidence was shown in support of the hypothesis
that CSF may detect amyloid-b accumulation in preclinical
Alzheimer’s disease earlier than amyloid PET (Palmqvist
et al., 2016). There is thus increasing evidence to suggest
that discussions surrounding the interchangeability of amyl-
oid-b biomarkers may be less applicable with respect to the
detection of cerebral amyloidosis in the preclinical phase of
Alzheimer’s disease. Speciﬁcally, isolated CSF positivity
may represent a proﬁle suitable for inclusion in clinical
trials of amyloidocentric agents (Hardy et al., 2014), or
related interventions targeting modiﬁable risk factors
(Ngandu et al., 2015). Given unresolved differences be-
tween current classiﬁcation schemes (Sperling et al., 2011;
Dubois et al., 2014, 2016), further follow-up studies to
verify progression to amyloid PET positivity, neurodegen-
erative changes and cognitive decline, are required.
A possible limitation of this study was the lack of gold
standard autopsy conﬁrmation. In addition to conﬁrming
or refuting clinical diagnoses for included subjects, post-
mortem data would possibly have allowed for an improved
understanding of PiB negative discordant cases, including
the potential effects of coincident pathologies. Autopsy data
would, moreover, have helped clarify the seven cases show-
ing discrepant classiﬁcations using visual and Centiloid
based methods; at least ﬁve of the six visually positive
cases, however, would likely have crossed the SUVr/
Centiloid threshold for positivity had partial volume cor-
rection (PVC) been applied. Though the lack of PVC stands
as a potential caveat, its application would likely only have
resulted in the relocation of a subset of isolated CSF+ cases
to the concordant positive quadrant. Future studies on
amyloid biomarkers, however, should examine the effect
of this type of correction. As a further caveat, the
INNOTEST amyloid-b42 ELISA would ideally have been
used instead of MSD, though the effect of this is likely to
have been minimal (Bjerke et al., 2016). Other possible
limitations include the relatively low number of cognitively
normal subjects and patients with FTD and VaD, as well as
the fact that APOE genotype data was not available for all
subjects. Lastly, CSF classiﬁcation cut-offs were established
with mixture modelling; while a robust approach for estab-
lishing unbiased thresholds, and used in several studies
(Buchhave et al., 2012; Palmqvist et al., 2014), these cut-
offs cannot be viewed as generalizable beyond the present
work.
Overall, the agreement levels between amyloid PET and
CSF amyloid-b42 here reported are in line with previous
studies, and support the strong agreement of these two
metrics in MCI and Alzheimer’s disease, with mainly iso-
lated low CSF amyloid-b42 in FTD, VaD and cognitively
normal subjects. While technical factors cannot be excluded
outright as contributing to measured amyloid-b42 and
amyloid-b40 levels in CSF assays, even when run in the
same time and place, continued discordance using centrally
reanalysed samples suggests that biological factors are also
at play. While further studies are required, in particular
longitudinal studies on amyloid biomarker trajectories,
with a focus on intraindividual change, our ﬁndings suggest
that, at least in a minority of subjects, these measures may
not be interchangeable, reﬂecting instead distinct but inter-
related processes. Future work using standardized amyloid
PET and CSF amyloid-b42, as well as post-mortem path-
ology data, will be critical to gaining an improved under-
standing of amyloid biomarker discordance.
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